236 related articles for article (PubMed ID: 37042865)
1. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
[TBL] [Abstract][Full Text] [Related]
2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
[TBL] [Abstract][Full Text] [Related]
3. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
[TBL] [Abstract][Full Text] [Related]
4. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
[TBL] [Abstract][Full Text] [Related]
6. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Kiladjian JJ; Vannucchi AM; Gerds AT; Gupta V; Verstovsek S; Egyed M; Platzbecker U; Mayer J; Grosicki S; Illés Á; Woźny T; Oh ST; McLornan D; Kirgner I; Yoon SS; Harrison CN; Klencke B; Huang M; Kawashima J; Mesa R
Hemasphere; 2023 Nov; 7(11):e963. PubMed ID: 37908862
[TBL] [Abstract][Full Text] [Related]
7. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
[TBL] [Abstract][Full Text] [Related]
9. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Mesa RA; Hudgens S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan DP; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins A; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Verstovsek S
Cancer Med; 2023 May; 12(9):10612-10624. PubMed ID: 37021939
[TBL] [Abstract][Full Text] [Related]
11. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
12. Momelotinib for the treatment of myelofibrosis with anemia.
Tremblay D; Mesa R
Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
[TBL] [Abstract][Full Text] [Related]
13. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
Leuk Lymphoma; 2024 Mar; ():1-13. PubMed ID: 38501751
[TBL] [Abstract][Full Text] [Related]
14. Myelofibrosis: an update on drug therapy in 2016.
Bose P; Verstovsek S
Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib in myelofibrosis.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
[TBL] [Abstract][Full Text] [Related]
16. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
17. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
18. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Tefferi A; Pardanani A; Gangat N
Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S
Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
